teaser
Two European drug firms are to collaborate on developing a promisingoncology compound. The UK’s Vernalis and France’s Servier will useVernalis’s proprietary drug discovery platform on an undisclosedtarget.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Vernalis chief executive Simon Sturge said thecollaboration with Servier followed on from a recent announcement thatanother of its partners, Novartis, had selected a second compound thatinhibits Hsp90, a target for a number of different cancer indications.
PharmaTimes 17/5/2007
